What Lytix Biopharma does

Lytix Biopharma ASA is a clinical-stage Norwegian biopharmaceutical company developing oncolytic molecule immunotherapies derived from host-defense peptides for the treatment of solid tumors. The company's lead candidate, ruxotemitide (LTX-315; also known as VP-315 under license), is administered intratumorally and works through a two-step mechanism: it lyses cancer cell membranes to release tumor antigens and immunostimulatory danger signals, then activates a broad T-cell response that produces durable systemic (abscopal) anti-tumor immunity. Ruxotemitide is in Phase II development for neoadjuvant resectable melanoma in combination with pembrolizumab (NeoLIPA study), and has reported 51% complete response and 97% clinical response rates in basal cell carcinoma under a 2017 exclusive worldwide license to Verrica Pharmaceuticals covering dermatologic indications. A second pipeline asset, LTX-401, targets deep-seated solid tumors including liver cancer via image-guided intratumoral delivery and is in late-stage pre-clinical development.

The company's underlying technology is a proprietary oncolytic peptide platform protected by an extensive patent estate across major pharmaceutical markets and supported by publications in journals such as the Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, Frontiers in Immunology, and OncoImmunology. Its Scientific Advisory Board includes Nobel Laureate James Allison. The business model is partnership-driven: Lytix is pre-revenue from product sales and generates income via licensing royalties and milestone payments from partners. Its sole commercial-stage counterparty is Verrica Pharmaceuticals for dermatology, and it is actively seeking additional co-development and outlicensing partners for ruxotemitide in Asia/APAC and for LTX-401 in deep-seated tumors. The company is listed on Euronext Growth Oslo under ticker LYTIX (ISIN: NO0010405780) since June 2021, converted from AS to ASA in April 2026, and as of February 2026 had 76,900,005 shares outstanding with NOK 72.4 million in cash and short-term investments at year-end 2025.

Name

Lytix Biopharma

Legal name

Lytix Biopharma ASA

Website

https://lytixbiopharma.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Lytix Biopharma ASA is a clinical-stage Norwegian biotech developing intratumoral oncolytic peptide immunotherapies (ruxotemitide, LTX-401) that lyse cancer cells and activate systemic immunity, serving cancer patients with solid tumors through licensing partnerships such as Verrica Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Immuno-oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industry

Medical Oncology (HLAKAFAB)

Keywords

• Oncolytic immunotherapy
• Immuno-oncology drugs
• Host-defense peptides
• Cancer therapeutics
• Neoadjuvant oncology

Headquarters

HQ city

Tromsø

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Royalties: Lytix generates revenue through licensing agreements with partners. Verrica Pharmaceuticals holds an exclusive worldwide license for dermatological oncology indications (basal cell carcinoma and squamous cell carcinoma). Lytix receives milestone payments and royalties from these licensing arrangements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Lytix Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of oncolytic molecule immunotherapies derived from host-defense peptides. Its lead asset ruxotemitide (LTX-315/VP-315) is being advanced toward registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with additional development in basal cell carcinoma via a licensing partnership with Verrica Pharmaceuticals. A second pipeline candidate, LTX-401, targets deep-seated solid tumors such as liver cancer using image-guided intratumoral delivery.

Product overview

Lytix Biopharma is a clinical-stage biotech company developing a platform of oncolytic molecule immunotherapies derived from host-defense peptides. The core product is ruxotemitide (LTX-315/VP-315), an oncolytic peptide approaching registrational studies for neoadjuvant melanoma in combination with pembrolizumab, with monotherapy indication in basal cell carcinoma via partnership with Verrica Pharmaceuticals. A second pipeline asset, LTX-401, is in pre-clinical development for deep-seated solid tumors including liver cancer. The company operates through direct clinical programs and licensing partnerships, focusing on intratumoral administration that destroys cancer cells and activates systemic immune responses.

Differentiator

Problem solved

Functional benefit

Products and services

• Ruxotemitide (LTX-315 / VP-315) First-in-class oncolytic peptide that destroys cancer cell membranes via intratumoral injection, releasing tumor antigens and immunostimulatory molecules that initiate a broad immune cell response. It is being developed for neoadjuvant resectable melanoma in combination with pembrolizumab, with monotherapy development in basal cell carcinoma via the Verrica partnership. Phase II data show a 51% complete response rate and 97% clinical response rate in basal cell carcinoma and approximately 90% pathological responses in combination with pembrolizumab in melanoma.
• LTX-401 Second-generation oncolytic molecule from Lytix's host-defense peptide platform, designed for deep-seated solid tumors such as liver cancer. It is administered via image-guided intratumoral delivery and has demonstrated proof-of-concept in animal models, including curing animals of liver cancer. The asset is in late-stage pre-clinical development and the company is actively seeking a development partner.

Quantifiable outcome

• 51% complete response rate in basal cell carcinoma Phase II study
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Verrica Pharmaceuticalscore/flagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2017Verrica Pharmaceuticals holds an exclusive worldwide license agreement with Lytix Biopharma to develop and commercialize ruxotemitide (LTX-315, VP-315) for dermatologic oncology conditions, including basal cell carcinoma and squamous cell carcinoma. Verrica has completed a Phase II study demonstrating 51% complete response rate and 97% clinical response rate in basal cell carcinoma patients. The partnership covers dermatology indications only.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Verrica Pharmaceuticals: Verrica is Lytix's exclusive worldwide licensee for dermatological oncology indications (BCC, SCC) of ruxotemitide (VP-315). It is a Nasdaq-listed dermatology-focused commercial-stage partner developing the same asset, making it the most directly comparable counterparty in Lytix's portfolio.
• Nykode Therapeutics: Norwegian clinical-stage biotech developing antigen-presenting therapeutic vaccines and immunotherapies for oncology and infectious diseases. Comparable as a Norway-headquartered, publicly-listed immuno-oncology platform biotech at a similar development stage.
• Replimune: Clinical-stage US biotech developing a portfolio of oncolytic immunotherapies (RP1, RP2, RP3) using engineered herpes simplex virus. Comparable as a pure-play oncolytic-immunotherapy developer pursuing intratumoral delivery and combination with checkpoint inhibitors.
• TILT Biotherapeutics: Finnish clinical-stage biotech developing oncolytic adenoviruses armed with cytokines (e.g., TILT-123) for solid tumor immunotherapy. Comparable as a Nordic-region oncolytic-immunotherapy company combining local tumor lysis with immune activation, similar in scale and stage.
• Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies (e.g., TBio-6517) combined with adoptive cell therapies for solid tumors. Comparable as an oncolytic-immunotherapy developer focused on turning 'cold' tumors 'hot.'
• Genelux Corporation: Clinical-stage biotech developing oncolytic vaccinia virus platforms (e.g., GL-ONC1, Olvi-Vec) for solid tumors. Comparable as a clinical-stage oncolytic-virus immunotherapy company pursuing intratumoral administration across multiple tumor types.
• Istari Oncology: Clinical-stage biotech developing PVSRIPO, an oncolytic poliovirus immunotherapy, with lead programs in glioblastoma and melanoma. Comparable as a clinical-stage intratumoral oncolytic-immunotherapy developer exploring checkpoint-inhibitor combinations.
• DNAtrix: Clinical-stage biotech developing oncolytic adenovirus DNX-2401 (tasadenoturev) for glioblastoma and other solid tumors. Comparable as a clinical-stage intratumoral oncolytic-virus immunotherapy developer.

Emerging players

• Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated INDUKINE molecules (PREDATOR platform) designed to be active within the tumor microenvironment. Comparable as an immuno-oncology company pursuing tumor-localized activation to overcome systemic immunotherapy limitations.

Broad incumbents

• BioNTech: Global commercial-stage immuno-oncology company developing mRNA cancer vaccines, bispecifics, and combination immunotherapies (including checkpoint-inhibitor combinations). Comparable as a leader in next-generation immuno-oncology combinations, though broader and far more advanced than Lytix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lytix-biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lytix Biopharma